• <li id="dxlul"></li>
    <wbr id="dxlul"></wbr>
    1. <li id="dxlul"></li>

      <button id="dxlul"></button>

      <progress id="dxlul"><legend id="dxlul"></legend></progress>

      Researchers & Partners

      Our vision is to discover, develop and deliver transformational medicines for patients through our internal discovery efforts and innovative collaborations and strategic business development opportunities.

      What We're Focused On

      What We're Focused On

      We concentrate our research and development efforts on our core therapeutic areas, and are pursuing multiple drug platforms for each.
      In the Pipeline

      In The Pipeline

      View the entire pipeline or customize your search by area of disease, development phase or modality.

      Investigating Combinations in Cancer Research

      Investigating Combinations in Cancer Research


      Our Research & Development Team

      Our Research & Development Team

      Our people are dedicated to unlocking the potential of innovative science. Our curiosity, persistence and desire to solve complex problems allow us to pursue our goal of delivering transformational medicines to patients.
      Our Research and Development Facilities

      Our Research and Development Facilities

      Take a look at the worldwide network of state-of the-art facilities where our discovery and development work happens.


      Partnering

      Partnering

      We actively seek partners with access to cutting-edge science that complements the innovation coming out of our own labs. Our business development team collaborates with R&D and organizations around the world to develop transformational medicines.


      Researcher Resources

      Independent Research

      Independent Research

      Bristol-Myers Squibb wishes to advance science through supporting novel, independent research that addresses unmet need surrounding our products and therapeutic areas.

      Clinical Trials

      Clinical Trials

      In 2017, we invested $4.8 billion* in R&D which included the discovery and development of new medicines for patients.

      *This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.?

      Evan Janovitz

      Input at Every Stage of Discovery

      Evan Janovitz leads a team of veterinary pathologists and allied scientists in the Discovery Toxicology organization.
      毛片基地